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Acetylcholinesterase Accelerates Assembly of
Amyloid-b-Peptides into Alzheimer's Fibrils:
Possible Role of the Peripheral Site of the Enzyme
Nibaldo C. Inestrosa, Alejandra Alvarez, associated with neuritic plaques (Mesulam, 1986; Geula
and Mesulam, 1989), in which it colocalized with amy-CristiaÂn A. PeÂrez, Ricardo D. Moreno,
Matias Vicente, Claudia Linker, loid-b peptide (Ab) deposits, including both the preamy-
loid diffuse deposits and the mature senile plaques (Car-Olivia I. Casanueva, Claudio Soto,*
and Jorge Garrido son et al., 1991; MoraÂ n et al., 1993). The diffuse
deposition of AChE togetherwith Ab, isparticularly inter-Departamento de BiologõÂa Celular y Molecular
Facultad de Ciencias BioloÂ gicas esting because it represents an early step in the devel-
opment of the senile plaques (Tagliavini et al., 1988),Pontificia Universidad
CatoÂ lica de Chile Santiago suggesting that AChE, an enzyme that is localized on
the presynaptic nerve terminal and also secreted as aChile
soluble form (MassoulieÂ et al., 1993) may be present
together with the soluble Ab at a very early stage of
amyloid plaque formation. Progressive deterioration ofSummary
memory and learning is a characteristic manifestation
of AD (Bondi et al., 1994). The molecular mechanismsAcetylcholinesterase (AChE), an important component
that underlie this phenomenon are still obscure, particu-of cholinergic synapses, colocalizes with amyloid-b
larly in the sporadic cases, which correspond to thepeptide (Ab) deposits of Alzheimer's brain. We report
great majority of AD patients (Katzman and Kawas,here that bovine brain AChE, as well as the human
1994). Therefore, there is a need to search for potentialand mouse recombinant enzyme, accelerates amyloid
reasons to explain the progressive cognitive decline information from wild-type Ab and a mutant Ab peptide,
AD. Recent support for a role of neocortical acetylcho-which alone produces few amyloid-like fibrils. The ac-
line in spatial memory has been obtained (Winkler ettion of AChE was independent of the subunit array
al., 1995); moreover, transgenic mice that overexpressof the enzyme, was not affected by edrophonium, an
human AChE in brain neurons showed a progressiveactive site inhibitor, but it was affected by propidium,
cognitive deterioration in the Morris water maze para-a peripheral anionic binding site ligand. Butyrylchol-
digm (Beeri et al., 1995). A number of studies with syn-inesterase, an enzyme that lacks the peripheral site,
thetic Ab in vitro have shown that this peptide aggre-did not affect amyloid formation. Furthermore, AChE
gates and forms amyloid fibrils similar to the filamentsis a potent amyloid-promoting factor when compared
found in the brains of patients with AD (Castano et al.,with other Ab-associated proteins. Thus, in addition
1986; Kirschner et al., 1987). A successful approach into its role in cholinergic synapses, AChE may function
the study of the structure and solubility of Ab has beenby accelerating Ab formation and could play a role
the alteration of the primary structure of the Ab frag-during amyloid deposition in Alzheimer's brain.
ments and the study of their properties (Soto et al.,
1994). The substitution of Glu-22→Gln, found in heredi-Introduction
tary cerebral hemorrhage with amyloidosis of the Dutch
type (Levy et al., 1990), yields a peptide with increasedAcetylcholinesterase (AChE) is the enzyme believed to
ability to form amyloid fibrils (Wisniewski et al., 1991).be involved in the hydrolysis of the neurotransmitter
On the other hand, the single mutation of Val-18→Alaacetylcholine in the central nervous system of mammals
induces a significant increment of the a-helical content(Inestrosa and Perelman, 1990; Taylor and Radic, 1994;
of Ab, and dramatically diminishes fibrillogenesis (SotoSilman et al., 1994). Its catalytic properties and role in
et al., 1995). It was our aim to investigate whether the insynaptic transmission are well-documented (Hall and
vivo colocalization of AChE and Ab could be reproducedKelly, 1971; Sussman and Silman, 1992). Alzheimer's
under in vitro conditions. If such interactions do occur,disease (AD), the most common form of dementia in
they might influence the process leading to amyloidadults, is characterized by extensive neuronal loss and
deposition and the appearance of AD. We report herethe presence of amyloid plaques and neurofibrillary tan-
that AChE induces amyloid fibril formation. Such effectgles (Selkoe, 1994; Soto et al., 1994). In 1984, Smith and
is independent of the source and structural polymor-Cuello suggested that a common feature shared by the
phism of the enzyme, is not affected by an active sitedifferent neuronal groups in which lesions occur in AD
inhibitor, is diminished by a nonselective bisquaternaryis the presence of AChE. This enzymatic activity de-
inhibitor and by a peripheral site blocker, and is notcreases in the brain of AD individuals, with a major de-
shared by butyrylcholinesterase (BuChE).cline in the G4 form (Atack et al., 1983; Fishman et al.,
1986) and a parallel increase in G1 and A12 forms (Younkin
et al., 1986; Arendt et al.,1992). This latter form increases Result
from nearly undetectable levels to almost 4% of total
activity in some areas (Younkin et al., 1986). Most of the jAChE Promotes Aggregation of Ab
cortical AChE activity present in AD brain was found Peptides and Amyloid Formation
The effect of AChE on the aggregation of Ab synthetic
peptides was studied through the turbidimetric mea-*Present address: Department of Neurology, New York University
Medical Center, New York, New York 10016. surement of the aggregation process (Jarret et al., 1993).
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During the 24 hr incubation period, the Ab peptide alone
became aggregated to a lesser extent (2-fold less) than
the Ab peptide plus purified brain G4 AChE (240 mM Ab
with AChE at 2.4 mM) (Figure 1A). To quantitate the level
of peptide aggregation further, we measured the amount
of remaining soluble peptide after incubation by a sedi-
mentation assay. Ab peptide aggregated only partially
in the absence of AChE (26%); however, addition of
AChE at 100:1 molar ratio increased theaggregate mate-
rial up to 80%. To quantitate partially the amount of
amyloid formed under each condition, we used a novel
method based on the fluorescence emission by thioflav-
ine-T bound to amyloid (Naiki et al., 1991; LeVine, 1993).
Thioflavine-T binds specifically to amyloid, and this
binding produces a shift in the emission spectra and a
fluorescence enhancement that is directly proportional
to the amount of amyloid formed (LeVine, 1993). Freshly
suspended Ab1±40 either alone or coincubated with AChE
in the fluorescence buffer showed no specific thioflav-
ine-T emission at 485 nm. During the incubation period,
there was a gradual increase of the fluorescence in both
240 mM Ab1±40 alone, and in Ab coincubated with 2.4
mM AChE up to 24 hr (Figure 1B). However, the rate of
increase was greater for Ab coincubated with AChE. In
fact, Ab1±40 coincubated with AChE displayed fluores-
cence values that were 2.8-fold higher than for Ab alone.
AChE alone (2±10 mM) showed no increase in fluores-
cence over this time period. Ab1±40 incubated with bovine
serum albumin, ubiquitin, collagen type IV, or fibronectin
gave similar fluorescence values to Ab alone (data not
shown). The next step was to study the effect of AChE
concentration upon amyloid formation. After 24 hr, an
increase in the fluorescence emission was observed
with increasing AChE concentrations up to 2.4 mM. At
1.2 mM (1:200 molar ratio, AChE:Ab1±40 peptide), 60% of
the maximal increase was seen (Figure 1C). These re-
sults are consistent with a faster aggregation of the
Ab1±40 in the presence of AChE.
Characterization of the Amyloid Fibrils
Induced by AChE
The morphology of the amyloid fibrils produced in the
presence of affinity purified G4 AChE form was examined
by electron microscopy after 5 days of incubation at
room temperature. Negatively stained Ab1±40 assembled
at (pH 7.4) revealed that the fibrous aggregates are com- Figure 1. AChE Induces Aggregation of the Ab1±40 Peptide and Amy-
posed of fibrils, both in the presence and absence of loid Formation
tetrameric AChE (Figures 2A and 2B). No morphological (A) The aggregation was measured by the turbidity at 405 nm. The
differences were detected between the fibrils formed Ab 1±40 peptide was incubated alone (240 mM) and with AChE (2.4
mM) at different times at room temperature in 0.1 M sodium acetateby Ab alone and by Ab incubated with AChE. In both
buffer, (pH 5.0). The values shown represent the mean of two differ-cases, the amyloid fibrils showed the typical features
ent experiments.
described, 7 nm±10 nm thick unbranched fibrils, up to (B) Thioflavine-T fluorescence of Ab1±40 alone and with AChE at differ-
3 mm in length (Castano et al., 1986; Kirschner et al., ent times of incubation. Fluorometric data from three identical sam-
1987). Although the morphology of the amyloid fibers ples in separate experiments, represent the mean 6 SD.
(C) AChE concentration dependence of Ab1±40 enhanced aggrega-was similar, the amount of these structures deposited
tion. Values represent the mean 6 SD of three separate experiments,on the electron microscope grids was higher in the pres-
with the exception of the molar ratio 10:1 (Ab:AChE) in which onlyence of AChE than in its absence, strengthening the
one experiment was carried out because 200 mg of enzyme was
results described above. No fibril formation was noted required for each assay.
with G4 AChE alone (Figure 2C). The above results sug-
gest that brain AChE constitutes an important cofactor
in Ab1±40 fibrillogenesis.
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Figure 3. Effect of AChE on Aggregation and Amyloid Formation byFigure 2. Electron Micrographs of Negatively Stained Preparations
Ab Analogs Containing Different Substitutionsof Ab1±40 Fibrils with and without AChE
Experimental conditions were those described in Figure 1. In bothAliquots of both preparations, Ab1±40 (A), Ab1±40 plus AChE (B) and
the turbidity measurement (A) and in the fluorescence studies (B),AChEalone (C) were adsorbed onto300-mesh Formvar-coated grids
the time of incubation was 24 hr. Different peptides (Ab1±40, AbVal-and negative-stained with 2% uranyl acetate. The specimens were
18→Ala and AbGalu-22→Gln) alone (1 mg/ml in 0.1 M Tris±HCl, [pH 7.4])viewed for fibrils with a Philips electron microscope. Original magni-
and with 2.4 mM AChE were incubated at room temperature. Thefication 80,0003.
mean 6 SD of three different experiments made in triplicate is
shown. The graph shows the fluorescence emission, in arbitrary
units, of thioflavine-T bound to the amyloid formed in the presence
AChE Induces the Mutant AbVal-18→Ala, but Not of each peptide with and without AChE.
the Dutch Variant AbGlu-22→Gln, to Form Amyloid
To better understand the effect of AChE on amyloid
formation, Ab analogs containing single amino acid sub- (9-fold) was observed after 24 hr of incubation (Figure
3B). These results indicate that AChE produces a greaterstitutions were used. First, we studied the single muta-
tion of Val-18→Ala that induces a significant increment effect on those peptides that have less b-sheet
structure.of a-helical structure and dramatically diminishes fibril-
logenesis (Soto et al., 1995). When the AbVal-18→Ala was The Dutch variant AbGlu-22→Gln is found in hereditary
cerebral hemorrhage with amyloidosis,Dutch type (Levyincubated at a concentration of 240 mM, only a small
increase in turbidity was observed after 24 hr of incuba- et al., 1990). This variant is highly amyloidogenic in vitro,
forming more stable fibrils more rapidly than wild-typetion. However, coincubation with purified brain AChE
(2.4 mM) resulted in a 5-fold increase in turbidity (Figure Ab1±40 (Wisniewski et al., 1991). To test the effect of AChE
on the aggregation of the Dutch variant, the peptide was3A). When the amyloid formation was measured by thi-
oflavine-T fluorescence, a clear increase in fluorescence incubated at 240 mM with AChE at 2.4 mM. Both turbidity
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Figure 4. Binding of Ab Analogs to AChE
Binding of different peptides with AChE was
studied by size exclusion chromatography
(Barrow et al., 1992). 10 mg of each peptide
(wild-type Ab1±40 and the variants AbVal 18→Ala
[A] and AbGlu-22→Gln [Q]) with AChE (molar ratio
of Ab:AChE, 15:1) for one hr at room tempera-
ture ina final volume of 40 ml. After incubation,
the samples were loaded in Sephadex G-25
columns preequilibrated in 0.1 M Tris±HCl,
(pH 7.4), and eluted by a brief spin. Eluted
samples were analyzed by SDS±polyacryl-
amide gels, using the Tris±Tricine system
(Schagger and van Jagow, 1987). The sam-
ples in the gel from left to right correspond
to AChE alone (lane 1), Ab1±40 peptide alone
(lane 2), Ab1±40 incubated with AChE (lane 3),
AbGlu-22→Gln (Q) with AChE (lane 4) and AbVal-
18→Ala (A) with AChE (lane 5). St1 AChE was
directly loaded in the gel (lane 6), as was St2
Ab1±40 peptide (lane 7). The molecular weight
markers are as follows: myoglobin (1±153)
16,950 Da; myoglobin I1II (1±131) 14,440 Da;
myoglobin I (56±131) 8,160 Da; myoglobin II
(1±55) 6,210 Da, and myoglobin III (132±153)
2,510 Da.
and fluorimetry showed no significant differences after Human and Mouse Recombinant AChE
Promotes Amyloid Formation24 hr, respectively (Figures 3A and 3B). These results
indicate that tetrameric AChE had little effect on the To make sure that the effect of AChE on amyloid forma-
tion was not the result of an Ab aggregation-promotingself-aggregation of the highly amyloidogenic Dutch vari-
ant. No differences were detected in the morphology contaminant that copurified with the bovine brain G4
form, amyloid formation was studied in the presence of(electron microscopy) of the amyloid fibrils formed by
the mutant AbVal-18→Ala, or the Dutch variant plus AChE both human and mouse recombinant AChE. The recom-
binant enzymes were purified by affinity chromatogra-compared with the wild-type Ab1±40 (data not shown).
Previously we have shown that Ab peptide binds AChE phy from the medium of transfected HEK-293 cells
(Velan et al., 1991; Bourne et al., 1995). Mouse AChE(Inestrosa et al., 1994, LatinoAmerican Congress of
Pharmacology, abstract; Alvarez et al., 1995). Therefore,
we tested the ability of the two Ab analog (AbVal-18→Ala and Table 1. Ab Binding and Formation of Ab Fibrils with Different
the Dutch variant) to bind G4 AChE using size exclusion AChE Forms
chromatography (Barrow et al., 1992). The esterase was
Molecular Form of AChE Ab Binding Ab Fibrils
preincubated for one hr with Ab1±40 and the Ab analog
Hydrophobic G4 AChE 35a 100bcontaining single amino acid substitutions. As shown
Hydrophilic G4 AChE 25 90in Figure 4, SDS±polycrylamide gels of the eluates of
Hydrophilic G1 AChE 20 85Sephadex G-25 filtration experiments indicated that
a Binding of Ab peptide to the different forms of AChEwas performedboth the wild-type Ab1±40, as well as the mutant AbVal-
using gel filtration analysis on Sephadex G-25 followed by SDS±
18→Ala(A) were able to bind AChE, while the Dutch variant PAGE as described in Experimental Procedures. Binding is ex-
AbGlu-22→Gln (Q) was not. These results are consistent with pressed as the percentage of total Ab peptide that bound to the
those presented above, showing that enhancement of AChE. The data are mean values of three separate experiments that
amyloid formation by AChE is relatively higher on less did not differ by more than 10%.
b The formation of Ab fibrils was established by electron microscopicamyloidogenic peptides (Ab1±40 and AbVal-18→Ala) than on
examination of the fibrils formed under the conditions described inhighly amyloidogenic variants such as AbGlu-22→Gln.
Figure 4. Data are expressed as the percentage of the total aggrega-
tion of Ab in separate grids, containing either the Ab peptide aloneDifferent Molecular Forms of AChE Bind Ab (30% aggregation) or the corresponding AChE form. The hydropho-
and Induce Amyloid Formation bic G4 AChE form containing the 20 kDa noncatalytic anchor domain
AChE exhibits considerable structural polymorphism was affinity purified from bovine caudate nucleus on an acridine±
Sepharose column, as described previously (Inestrosa et al., 1987).(Inestrosa and Perelman, 1989; MassoulieÂ et al., 1993);
The hydrophilic G4 AChE was prepared from the hydrophobic G4therefore, we studied the ability of several molecular
after proteolytic digestion using proteinase K, and the monomericforms of AChE to promote the assembly of Ab1±40 into
hydrophilic AChE form was prepared from the hydrophobic G4 formamyloid fibrils and to bind the Ab peptide. As shown in by mild proteolytic digestion with trypsin (Fuentes et al., 1988). In
Table 1, hydrophobic and hydrophilic tetrameric (G4) both cases, the hydrophilic G4 and the monomeric forms of AChE
AChE, as well as hydrophilic monomeric (G1) AChE were separated from the reaction products of each proteolytic di-
gestion plus the corresponding protease by subsequent chromatog-forms, were able to bind Ab1±40 and to induce amyloid
raphy on acridine±Sepharose as described for the native G4 AChEfibril formation. These results suggest that the capacity
(Inestrosa et al., 1987). In addition, for each enzyme form, homoge-of AChE to promote assembly of Ab into amyloid fila-
neity was established by SDS±PAGE.
ments resides in the molecular structure of its monomer.
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thioflavine-T fluorescence. In both cases, the effect is
appproximately 75% of that observed with the affinity-
purified bovine brain G4 tetramer. These results indicate
that AChEs from different sources are able to accelerate
the aggregation of Ab1±40 into amyloid fibrils, making
unlikely that an aggregation-promoting factor other than
AChE could be responsible for the results presented in
this paper.
Propidium, a Peripheral Anionic Site Ligand,
Affects the Formation of Amyloid
Induced by AChE
Besides active site inhibitors, AChE activity is also inhib-
ited by peripheral anionic site ligands (Radic et al., 1991;
Eichler et al., 1994). When the effect of AChE on amyloid
formation was studied in the presence of propidium,
an exclusive peripheral anionic site ligand (Taylor and
Lappi, 1975), this compound inhibited almost 75% of the
enhancement of amyloid formation triggered by AChE
(Figure 6A). Bisquaternary ligands are well-known inhibi-
tors of AChE (Bergmann et al., 1950; Bergmann and
Segal, 1954) and their inhibitory capacity has been as-
cribed to their ability to span the distance between the
active center and the peripheral anionic site (Main,
1976). When the effect of AChE on amyloid formation
was studied in the presence of the nonselective bisquat-
ernary inhibitor decamethonium, this compound inhib-
ited nearly 80% of the enhancement of amyloid fibril
formation (Figure 6A). However, BW 284C51, a selective
bisquaternary inhibitor, did not inhibit amyloid formation
at 2 mM. On the other hand, when the cationic active
center ligand edrophonium (Wilson and Quan, 1958; Sil-
man et al., 1994) was included, no effect on amyloid
formation was observed (Figure 6A).
These results suggest that the catalytic active center
of AChE does not participate in the interaction of the
enzyme with the Ab peptide, whereas it is possible that
the peripheral anionic binding site of AChE may be in-
volved in amyloid formation.
Figure 5. HuAChE and mAChE Recombinants Promote the Assem-
bly of Ab1±40 Peptide on Amyloid Fibrils BuChE Does Not Promote
(A) Hydrodynamic analysis of purified brain bAChE, HuAChE, and Amyloid Formation
mAChE. A sample of each purified enzyme (50 ml), supplemented BuChE shares many structural and physicochemical
with sedimentation standards, was centrifuged in a 5%±20% su- properties with AChE (Chatonnet and Lockridge, 1989),
crose gradient inthe presence of Triton X-100, and thenfractionated,
and it has been detected in senile plaques and also inand the AChE activity was determined by the Ellman method (Ellman
neurofibrillary tangles (Mesulam et al., 1987; GoÂ mez-et al., 1961).
(B) Amyloid formation by AChE from several sources. Purified G4 Ramos et al., 1992) in which it colocalized with the Ab
bovine AChE, and HuAChE recombinant, containing 90% of G2 form peptide (MoraÂ n et al., 1993). Therefore, we evaluated
and 10% of G1 form, and mAChE recombinant monomeric G1 AChE whether BuChE can affect the known spontaneous in
form were incubated with 240 mM AbVal-18→Ala peptide (1 mg/ml) with vitro amyloid formation. Thioflavine-T fluorimetry of
or without bAChE (2.4 mM), HuAChE (3.6 mM) and mAChE (9.6 mM)
Ab1±40 incubated with BuChE, at 240 mM and 2.4 mM,for 48 hr at room temperature. Then, amyloid formation was quanti-
respectively, showed no significant differences after 24fied by thioflavine-T fluorescence. Data from three different samples
run in parallel, results are mean 6 SD. hr (Figure 6B). The same results were obtained when
the relative concentration of BuChE in relation to Ab
was increased in the incubation sample (2.4 mM BuChE
with 120 and 60 mM Ab1±40). Because BuChE lacksTyr-72,(mAChE) sediments as a 4.8 S monomeric G1 form and
human AChE (HuAChE) sediments as two molecular Tyr-124 and Trp-286, residues that form the peripheral
anionic binding site of AChE (Harel et al., 1992; Radicforms of 6.5 S and 10.7 S, which correspond to G2 and
G4 species (Figure 5A). Both mAChE and HuAChE were et al., 1993; Barak et al., 1994), it is possible that the
absence of such amino acids may be involved in theassayed for their capacity to accelerate amyloid forma-
tion. As Figure 5B indicates, coincubation of Ab with lack of effect of BuChE on the formation of amyloid
fibrils.either mAChE or HuAChE resulted in a clear increase in
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Table 2. AChE Is an Efficient Promoter of Amyloid Formation
Amyloid Formation Relative
Protein (Thioflavine-T Fluorescence) Enhancement
Ab alone 14.1 6 2.7 1.00
Ab plus apoE3 17.6 6 3.9 1.25
Ab plus a1-ACT 19.2 6 4.1 1.36
Ab plus AChE 58.2 6 3.7a 4.12
Aliquots of the Ab1±40 peptide in a concentration of 1 mg/ml (240
mM) were incubated for 24 hr in 0.1 M Tris±HCl (pH 7.5) at room
temperature in the presence of 2.4 mM of AChE, apolipoprotein
E3 (apoE3), and a1-antichymotrypsin (a1-ACT) (1:100 molar ratio).
ApoE3 and a1-ACT alone did not produce fluorescence above the
background. In the case of AChE alone, the value of fluorescence
was 2. The values shown correspond to the mean fluorescence 6
SD of three different experiments made in duplicate.
a Student's t test, p # 0.001.
Discussion
AChE Is an Amyloid-Promoting Factor
In the present study, the ability of purified AChE to pro-
mote the assembly of Ab1±40 peptide into amyloid fila-
ments was demonstrated. AChE induced a higher in-
crease in the amount of amyloid formed on a poorly
amyloidogenic Ab analog created by substituting ala-
nine for valine at position 18. Conversely, AChE was not
able to increase the formation of amyloid by the Dutch
variant of Ab, in which a Glu-22→Gln substitution gener-
ates a higher amyloidogenic variant (Wisniewski et al.,
1991; Soto et al., 1995). These results are in agreement
with our recent findings that AChE modulates amyloid
formation by inducing a conformational change in Ab
(Alvarez et al., 1995). Alternatively, AChE could act as a
heterogeneous nucleator, increasing the rate of fibrillo-
Figure 6. Propidium, but Not Active Site Inhibitors, Inhibits Amyloid genesis, especially in the less amyloidogenic peptides.
Formation Induced by AChE An additional possibility is that AChE could bind to and
(A) Amyloid formation was quantified through thethioflavine-T assay stabilize the growing amyloid fibrils.
(Naiki et al., 1989; LeVine,1993). Aliquots of AbVal-18→Ala in a concentra-
tion of 1 mg/ml (0.25 mM) were incubated, with or without 2.4 mM
AChE in the presence of 50 mM propidium, 100 mM decamethonium, AChE from Different Sources and Quaternary
2 mM BW284C51, and 100 mM edrophonium for 24 hr in 0.1 M
Structure Promotes Amyloid FormationTris±HCl (pH 7.5), at room temperature. Then, amyloid formation
Human, bovine, and mouse AChE were able to acceler-was quantified by thioflavine-T fluorescence.
ate the aggregation of Ab1±40 into amyloid fibrils. These(B) BuChE does not promote amyloid formation. Aliquots of Ab1±40
(1 mg/ml) were incubated, with or without 2.4 mM BuChE or AChE results indicate that an AChE-specific domain, not re-
for 24 hr in 0.1 M Tris±HCl, (pH 7.5), at room temperature. Then, the lated to different species, is involved in such a function.
amyloid was quantified by the thioflavine-T method. As in (A), the The fact that recombinant HuAChE promotes amyloid
values shown correspond to the mean 6 SD of three different experi-
formation is interesting because AD affects human be-ments made in duplicate.
ings, and therefore, if one desires to make any sugges-
tion about the effect of AChE on AD pathology, it is
mandatory to demonstrate that HuAChE is able to pro-AChE Is a Potent Amyloid-Promoting Factor
We examined the relative ability of purified brain G4 mote amyloid formation. Also, recent studies have
shown that the transgenic expression of HuAChE in-AChE, recombinant apolipoprotein E3 (apoE3), and a1-
antichymotrypsin (a1-ACT) to promote amyloid forma- duces progressive memory deterioration in mice (Beeri
et al., 1995), a fact that may be related to the effecttion. As shown in Table 2, a small effect was observed
with apoE3. This result is consistent with recent studies described in this paper, particularly considering that G1
or A12 AChE forms may be involved. From a biologicalshowing that recombinant apoE is not an efficient pro-
moter of Ab fibrillogenesis (Castano et al., 1995; Evans point of view, it is interesting that two different recombi-
nant enzymes (HuAChE and mAChE) were able to accel-et al., 1995). Unexpectedly, a1-ACT showed only a rela-
tively weak capacity to form amyloid (Ma et al., 1994). erate amyloid formation, because it would be relatively
easy to employ site-directed mutagenesis and molecu-We conclude that AChE is an effective promoting factor
of amyloid formation. lar modeling techniques to examine different mutants
AChE Promotes Formation of Amyloid Filaments
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of AChE for their capacity to bind Ab and to promote with this possibility. Barak et al. (1994) proposed that
amyloid formation. the peripheral anionic site of HuAChE consists of a num-
The quaternary structure adopted by AChE did not ber of binding sites close to the entrance of the active
affect the capacity of the enzyme to accelerate the amy- site gorge. Their data suggest that propidium, deca-
loid formation; in fact, tetrameric (both hydrophobic and methonium, and BW284C51 bind to the peripheral site
hydrophilic), as well as dimers and monomers of the in a distinctive manner and that the nature and extent
enzyme, were able to accomplish such a function. This of participation of the individual residues is ligand de-
is important because changes in the distribution of the pendent. This functional degeneracy is in part the result
AChE molecular forms occur during AD (Younkin et al., of the ability of the Trp-286 indole moiety to interact
1986; Nakamura et al., 1990; Arendt et al., 1992), includ- either via stacking (with propidium), via p-cation attrac-
ing the appearance of an anomalous molecular form of tions (with decamethonium), or aromatic±aromatic inter-
this enzyme (Navaratnam et al., 1991). actions (with BW284c51). Another view is provided by
the recent analysis of the crystal complex of AChE and
fasciculin, a 61 amino acid peptide isolated from mambaThe Catalytic Active Center of AChE Is Not
venoms (Bourne et al., 1995; Harel et al., 1995). ThisRequired for Amyloid Formation
toxin binds to the residues belonging to the peripheralSome features of AChE suggest that the enzyme may
anionic site of AChE, although other residues like Pro-78have a potential noncatalytic function(s) other than ace-
and Gly-342 in mAChE also contribute to the fasciculintylcholine hydrolysis (Layer et al., 1993; MassoulieÂ et al.,
binding site. Whether they should also be considered1993). Our results, showing that the ability of AChE to
as part of the peripheral anionic site is not certainpromote amyloid fibril formation was not affected by a
(Bourne et al., 1995; Harel et al., 1995). In this context,specific active center inhibitor, indicate that the enzyme
we recently found that 1 nM fasciculin inhibits only 30%was able to perform such function by using a structural
of the enhancement of amyloid formation triggered bydomain other than the activecenter. This result suggests
the bovine brain G4 AChE (C. A. P., F. Dajas., N. C.that the aggregation of the Ab peptide promoted by
I., unpublished data). Therefore, it is possible that theAChE is independent of its well-known catalytic activity.
interaction of the Ab peptide with the peripheral anionic
binding site(s) of AChE may be more complex than we
A Hydrophobic Environment Close would expect, by simply following the well-established
to the Peripheral Anionic Binding specificity of the enzyme. Of course, further studies are
Site(s) of AChE Is Probably Involved necessary to identify the structural AChE domain in-
in the Formation of Amyloid
volved in the interaction with the Ab peptide. For the
In 1950, on the basis of binding studies of bisquaternary
time being, we would like to propose the following as
compounds to AChE, Nachmansohn and coworkers
a working hypothesis: the domain of AChE involved in
proposed the existence of a second anionic site on the
the acceleration of amyloid formation is related to a
enzyme, which became known as the peripheral anionic
hydrophobic environment close to theperipheral anionicsite (Bergmann et al., 1950). Later, Changeux (1966)
binding site(s) of the catalytic subunit of the enzyme.showed that the action of reversible inhibitors of AChE
could not be explained simply on the basis of a single
site, but rather that certain ligands affect catalysis
Role of Other Senile Plaque-Associatedthrough binding to an allosteric site. The ligand propid-
Proteins in Amyloid Formationium binds to AChE and is selective for the peripheral
Amyloid plaque is an ordered, fibrous protein aggregatesite (Taylor and Lappi, 1975). The peripheral site of AChE
characteristic of AD brain (Lansbury, 1992; Soto et al.,appears to be located at or close to the enzyme surface,
1994). It has been suggested that endogenous factorsnear the entrance of the active site gorge (Weise et al.,
that accelerate amyloid deposition could play a signifi-1990; Amitai and Taylor, 1991; Sussman et al., 1991;
cant role in the pathogenesis of AD (Jarrett and Lans-Sussman and Silman, 1992; Silman et al., 1994), and
bury, 1993). Although the present investigation has de-peripheral site ligands might act by partially obstructing
termined that AChE is an Ab-associated component thatthe entrance to the gorge (Taylor and Radic, 1994).
promotes amyloid fibril formation, it is possible thatWithin this context, it is possible that the presence of a
other Ab-associated proteins may be involved. Theseperipheral site blocker will not permit the Ab peptide to
include amyloid-P component (Kalaria et al., 1991), apointeract with AChE, determining a lack of effect of the
E (Wisniewski and Frangione, 1992), apo J (Ghiso etesterase over the amyloid fibril formation process. Con-
al., 1993), a1-ACT (Ma et al., 1994), extracellular matrixsistent with this possibility is the finding that BuChE,
components (Brandan and Inestrosa, 1993), and proteo-an enzyme that lacks most of the amino acids of the
glycans (Snow et al., 1988). Recent studies indicate thatperipheral anionic site (Harel et al., 1992; Vellom et al.,
perlecan, a heparan sulfate proteoglycan, infused to-1993; Radic et al., 1993), was not able to stimulate the
gether with Ab1±40 into rat brain, induces the formationformation of amyloid fibrils. Our results, which show that
of amyloid deposits adjacent to the infusion site (Snowthe ability of AChE to promote amyloid formation was
et al., 1994). Therefore, it is possible that AChE and ainhibited by propidium and decamethonium, point to
heparan sulfate proteoglycan might play a role in pro-the involvement of the peripheral anionic binding site
moting the assembly of Alzheimer Ab peptide into fila-in the interaction of the enzyme with the Ab peptide;
however, the result with BW284c51 is not consistent ments. In this context, it is interesting to mention that
Neuron
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Experimental Proceduresasymmetric AChE, an enzyme form that increasessever-
alfold in AD brain (Younkin et al., 1986) and is apparently
Materials,bound to senile plaques (Nakamura et al., 1990), binds Synthetic Peptides and Proteins
heparan sulfate proteoglycans and heparin (Brandan et Ab peptide corresponding to residues 1±40 of the human wild-type
al., 1985; Deprez and Inestrosa, 1995). Further studies sequence, and peptides with amino acid substitutions, were synthe-
sized by Chiron Corporation Incorporated, Emeryville, CA. The vari-of amyloid formation in vitro, using additional amyloid-
ant peptides were a mutant peptide AbVal-18→Ala, containing a valineassociated proteins, should be carried out in order to
to alanine substitution (Soto et al., 1995), and the Dutch variant ofdetermine the relative importance of their eventual con-
Ab, containing a single amino acid substitution, Glu-22→Gln (Levy
tributions. et al., 1990). Results for the Ab1±40 peptide were replicated with
peptides from Sigma. Human serum BuChE was a gift of Dr. Oksana
Lockridge, University of Nebraska, Omaha, NE. Recombinant apoE3
isoform was obtained from PanVera (Madison, WI). a1-ACT wasHas AChE Any Role in Triggering Amyloid
purchased from Calbiochem (La Jolla, CA). Other reagents, whereDeposition in AD?
not otherwise specified, were obtained from commercial sources.The cholinergic system is affected in AD (Perry et al.,
1978; Whitehouse et al., 1981; Coyle et al., 1983; Geula Substrates and Inhibitors
and Mesulam, 1994), and despite a decrease in the level AChE was assayed with acetylthiocholine iodide (Sigma) as sub-
of AChE in the AD brain, the enzyme accumulates within strate. The inhibitors 3,8-diamino-5-(39-trimethylammonium)propyl-
6-phenyl-phenanthridinium diiodide (propidium), 1,10-bis (trimethyl-amyloid plaques (Geula and Mesulam, 1989; GoÂ mez-
ammonium)decane (decamethonium), di(p-allyl-N-dimethylamino-Ramos et al., 1992; Wright et al., 1993). Moreover, pri-
phenyl)-pentane-3-one (BW284C51), and ethyl(m-hydroxyphenyl)-mate studies have shown that AChE may be deposited
dimethylammonium chloride (edrophonium) were all purchased
in plaques during the early stages of amyloid formation from Sigma.
(Struble et al., 1982). In mature plaques, AChE is pre-
dominantly associated with the amyloid, rather than with Purification of Bovine Brain AChE
The tetrameric G4 AChE form (sedimentation coefficient 10.7 S) wasthe neuritic component (Carson et al., 1991). Within this
purified from bovine caudate nucleus, using acridine-affinity chro-context, the fact that AChE behaves as an amyloid-
matography (Inestrosa et al., 1987). Both specific activities (6,000promoting factor suggests that the enzyme may play
U/mg protein), and staining intensities following polyacrylamide gel
a role in amyloid deposition. Regarding the neuronal electrophoresis (a single band of 68 kDa) were used to verify purity.
damage and the deposition of amyloid fibrils that exhibit
a restricted localization in Alzheimer's brain (Terry et al., Recombinant AChEs
Recombinant human AChE was purchased from Sigma, and con-1994), it is unclear how the low (nanomolar) levels of
sists of 90% of dimers (G2, 6.5 S) and 10% of tetramers (G4, 10.7 S)soluble Ab present in the brain (Selkoe, 1994) give rise
of catalytic subunits (Velan et al., 1991), and a G1 (4.8 S) mouseto aggregated Ab in the form of stable amyloid plaques.
recombinant. mAChE was a gift of Dr. Palmer Taylor, University of
Therefore, the availability of the Ab peptide itself is not California, San Diego, La Jolla, CA.
a rate-limiting step in its deposition (Selkoe, 1994) and
other local promoting factors like AChE may play an Aggregation Studies of Ab Peptides: Turbidity
Lyophilized aliquots of the peptides were resuspended in 0.1M so-active role in the formation of mature toxic plaques (Iver-
dium acetate, (pH 5.0). At various times, the aggregation was de-sen et al., 1995). Loss of cellular AChE and deposition of
tected via turbidity measurements at 400 nm, as described pre-the secreted enzyme within preamyloid diffuse plaques
viously (Jarret et al., 1993; Soto et al., 1995). Specifically, Ab1±40
and senile plaques (Struble et al., 1982; MoraÂn et al., synthetic peptide (240 mM) was incubated alone or in the presence
1993), may be due to the degeneration of AChE-con- of affinity purified AChE (2.4 mM) at a molar ratio Ab:AChE of 100:1.
The incubation was carried out at room temperature in phosphate-taining neurons (Geula and Mesulam, 1994) some of
buffered saline, (pH 7.4). Sedimentation assay Ab1±40 peptide waswhich may not be cholinergic (Mesulam and Geula,
incubated for 5 days in 0.1 M Tris±HCl, (pH 7.4), at room temperature.1988). The importance of AChE in AD was emphasized
The soluble peptide was separated from the aggregated one, by
by Smith and Cuello (1984), who indicate that different centrifugation at 14,000 rpm for 15 min. Aliquots of the supernatant
cell groups in which lesions occur in AD share as a were analyzed by HPLC using a Waters apparatus. Absorbance
was monitored at 220 nm. The percentage of the nonsedimentablecommon feature their high content of AChE. In this con-
peptide was measured by comparing the area of the peak corre-text, it was recently proposed that the alteration of the
sponding to the soluble peptide at 5 days of incubation with aAChE systems, especially those more vulnerable in AD
nonincubated sample.
such as the lightly stained neurons located in the ento-
rhinal cortex, the CA1/subiculum of the hippocampus, Amyloid Detection in Suspension: Thioflavine-T
and the amygdala, are the first to be affected in the Based Fluorometric Assay
Aliquots of peptides at the indicated concentrations were incubatedpathological process of AD (Shen, 1994). Consistent
for different times at room temperature in 0.1M Tris±HCl, (pH 7.4).with the possibility that AChE would play a relevant role
For coincubation experiments, aliquots of AChE to a final molar ratioin AD is a recent work of Soreq and coworkers (Beeri
of 100:1 were added. To quantitate amyloid formation we used a
et al., 1995), showing that transgenic expression of Hu- thioflavine-T fluorescence method as described (LeVine, 1993; Soto
AChE induces progressive cognitive deterioration in et al., 1995). Thioflavine-T binds specifically to amyloid and this
binding produces a shift in its emission spectrum and a fluorescentmice. Therefore, it is intriguing to speculate that AChE
signal proportional to the amount of amyloid formed (Naiki et al.,may have a more fundamental role in amyloid formation,
1991). After incubation, Ab peptides were added to 50 mM glycine,by providing a potential molecular link between the de-
(pH 9.0), 1.5 mM thioflavine-T in a final volume of 2 ml. Fluorescence
generation of AChE-containing presynaptic nerve termi- was monitored at excitation 435 nm and emission 485 nm using a
nals and the formation of senile plaques in Alzheimer's Hitachi F-2000 spectrofluorometer. A time scan of fluorescence was
performed, and three values after the decay reached the plateaubrain.
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(around 300 s) were averaged after subtracting the background Amitai, G., and Taylor, P. (1991). Characterization of peripheral an-
ionic site peptides of AChE by photoaffinity labeling with monoazi-fluorescence of 1.5 mM thioflavine-T. For coincubation experiments,
fluorescence of AChE alone preincubated at 10 mM was determined. dopropidium (MAP). In Cholinesterases: Structure, Function, Mech-
anism, Genetics and Cell Biology, J. MassoulieÂ , F. Bacou, E.A.The esterase or the Ab peptide with or without 0.1% Triton X-100
gave fluorescence values of 2 or less. To study the effect of the Barnard, A. Chatonnet, B.P. Doctor, and D.M. Quinn, eds. (Washing-
ton D.C.: American Chemical Society), p. 285.AChE concentration on the Ab aggregation, Ab1±40 at 240 mM in 0.1
M Tris±HCl, (pH 7.4) was incubated for 24 hr in the presence of Arendt, T., BruÈckner, M.K., Lange, M., and Bigl, V. (1992). Changes
increasing concentrations of AChE and fluorometry performed as in acetylcholinesterase andbutyrylcholinesterase in Alzheimer's dis-
described above. All of the experiments were performed in triplicate. ease resemble embryonic development. A study of molecular forms.
Neurochem. Int. 21, 381±396.
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